{"id":"NCT03907878","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines","officialTitle":"A Multi-center, Open-label Study to Investigate the Safety/Tolerability and Efficacy of Ligelizumab (QGE031) in the Treatment of Adult Japanese Patients With Chronic Spontaneous Urticaria (CSU) Inadequately Controlled With H1 Antihistamines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-13","primaryCompletion":"2022-01-26","completion":"2022-01-26","firstPosted":"2019-04-09","resultsPosted":"2024-03-08","lastUpdate":"2025-03-06"},"enrollment":66,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"BIOLOGICAL","name":"Ligelizumab","otherNames":["QGE031"]}],"arms":[{"label":"Ligelizumab 120 mg per 1 mL qw4","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the safety and efficacy of ligelizumab in adult Japanese subjects with CSU, who remain symptomatic despite treatment with H1-antihistamines (AHs) at locally approved doses.\n\nThe study population consisted of 66 male and female subjects aged â‰¥ 18 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-AH.\n\nThis was a Phase III multi-center, open-label, single arm study. There was a screening period of up to 28 days, a 52 week treatment period, and a 12 week post-treatment follow-up period.","primaryOutcome":{"measure":"Safety and Tolerability of Ligelizumab 120 mg q4w Treatment for 12 Months","timeFrame":"64 weeks","effectByArm":[{"arm":"Ligelizumab 120 mg Per 1 mL qw4","deltaMin":53,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1387"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":66},"commonTop":["Eczema","Nasopharyngitis","Pyrexia","Back pain","Dermatitis contact"]}}